Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Children's Oncology Group
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Children's National Research Institute
Mayo Clinic
Baylor College of Medicine
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Nationwide Children's Hospital
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
City of Hope Medical Center
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Ann & Robert H Lurie Children's Hospital of Chicago
Children's Hospitals and Clinics of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
University of Virginia
Bayer
National Cancer Institute (NCI)
Sumitomo Pharma America, Inc.
New York Medical College
Children's National Research Institute
Children's National Research Institute
Florida International University
Children's Hospitals and Clinics of Minnesota
MacroGenics
West China Hospital
Children's Oncology Group
Dana-Farber Cancer Institute
Barbara Ann Karmanos Cancer Institute